Pfizer's COVID-19 vaccine trial data shows long-term efficacy in adolescents

Access to the comments Comments
By Reuters
Pfizer's COVID-19 vaccine trial data shows long-term efficacy in adolescents
Pfizer's COVID-19 vaccine trial data shows long-term efficacy in adolescents   -   Copyright  Thomson Reuters 2021   -  

<div> <p> -Pfizer Inc said on Monday its <span class="caps">COVID</span>-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.</p> <p>A two-dose series of the vaccine was 100% effective against <span class="caps">COVID</span>-19, measured seven days through over four months after the second dose, the company said.</p> <p>The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.</p> <p>Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.</p> <p>The vaccine was authorized for emergency use in people aged 12-15 years by the U.S. Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August.</p> </div>